Radiation dosimetry and first therapy results with a 124I/ 131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 7, 2014, Pages 1280-1292

  Zechmann, Christian M ^a   Afshar Oromieh, Ali ^a   Armor, Tom ^b   Stubbs, James B ^c   Mier, Walter ^a   Hadaschik, Boris ^a   Joyal, John ^b   Kopka, Klaus ^d   Debus, Jürgen ^a   Babich, John W ^b,e   Haberkorn, Uwe ^a,d  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b A Subsidiary of Lantheus Holdings   (United States)

^c Radiation Dosimetry Systems RDS Inc   (United States)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Absorbed dose estimates; Biodistribution; Dosimetry; Prostate cancer; PSMA targeting; Radioiodinated PSMA ligand

Indexed keywords

CHOLINESTERASE; GALLIUM 68; IODINE 124; IODINE 131; LUTETIUM 177; MIP 1095 I 124; MIP 1095 I 131; MONOCLONAL ANTIBODY J591; MONOCLONAL ANTIBODY J591 LU 177; MONOCLONAL ANTIBODY J591 Y 90; POTASSIUM PERCHLORATE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; YTTRIUM 90; 2-(3-(1-CARBOXY-5-(3-(4-IODOBPHENYL)UREIDO)PENTYL)UREIDO)PENTANEDIOIC ACID; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; GLUTAMIC ACID DERIVATIVE; MEMBRANE ANTIGEN; RADIOACTIVE IODINE; UREA;

ABLATION THERAPY; ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BONE PAIN; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMPASSIONATE USE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG UPTAKE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; INTESTINE WALL; ISOTOPE LABELING; KIDNEY; KIDNEY CLEARANCE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION TEST; LACRIMAL GLAND; LIMIT OF QUANTITATION; LIVER; LIVER FUNCTION TEST; MALE; METASTASIS; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; PET-CT SCANNER; PROSTATE BIOPSY; PROSTATECTOMY; RADIATION DOSE; RADIONUCLIDE DOSE CALIBRATOR; RADIOTHERAPY SOFTWARE; SALIVARY GLAND; TARGET ORGAN; TREATMENT RESPONSE; TUMOR ABLATION; TUMOR VOLUME; WHOLE BODY PET; WHOLE BODY SCINTISCANNING; XEROSTOMIA; ANALOGS AND DERIVATIVES; METABOLISM; MIDDLE AGED; ORGANS AT RISK; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIATION RESPONSE; RADIOGRAPHY; RADIOMETRY; SAFETY; SCINTISCANNING; TREATMENT OUTCOME;

AGED; ANTIGENS, SURFACE; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; ORGANS AT RISK; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; SAFETY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; UREA;

EID: 84903709596     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2713-y     Document Type: Article

References (25)

1. American Cancer Society, Inc., Surveillance Research; Cancer Facts & Figures, 2012.
2. National Cancer Institute, Surveillance Epidemiology and End Results. SEER stat fact sheets: prostate. Available from: http://seer.cancer.gov/ statfacts/html/prost.html
3. Litwin MS et al. Epidemiological trends and financial outcomes in radical prostatectomy among medicare beneficiaries, 1991 to 1993. J Urol. 1998;160:445-8. (Pubitemid 29476695)
4. Ahmedin J et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
5. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000;60:5237.
6. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528-39.
7. Vallabhajosula S, Goldsmith SJ, Kostakoglu L, Milowsky MI, Nanus DM, Bander NH. Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin Cancer Res. 2005;11:7195s.
8. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol. 2004;22(13):2522-31. (Pubitemid 41103739)
9. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, et al. Phase I trial of 177Lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23:4591-601. (Pubitemid 46224061)
10. 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med. 2005;46:850-8.
11. Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH et al. Phase II study of lutetium-177 labeled anti-prostate-specific membrane antigen (PSMA)monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Can Res 2013. Aug 26 Epub ahead of print.
12. Maresca KP, Hillier SM, Femia FJ, Keith D, Barone C, Joyal JL, et al. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem. 2009;52(2):347-57.
13. Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009;69:6932-40.
14. 131I]MIP-1466, a small molecule prostate-specific membrane antigen (PSMA) inhibitor for targeted radiotherapy of prostate cancer (PCa). J Nucl Med. 2012;53 Suppl 1:170.
15. Hillier S, Merkin R, Maresca K, Zimmerman C, Barrett J, Tesson M, et al. [131I]MIP-1375, a small molecule prostate-specific membrane antigen (PSMA) inhibitor for targeted therapy of prostate cancer (PCa). J Nucl Med. 2011;52 Suppl 1:361.
16. Levitzki A. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Annu Rev Pharmacol Toxicol. 2013;53:161-85.
17. Eder M, Schafer M, Bauder-Wust U, Hull WE, Wangler C, Mier W, et al. 68Ga-Complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjugate Chem. 2012;23:688-97.
18. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-7. (Pubitemid 43733519)
19. Barrett JA, Coleman RE, Goldsmith SJ, Vallabhajosula S, Petry NA, Cho S, et al. First-in-man evaluation of two high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med. 2013;54(3):380-7.
20. Troyer JK, Beckett ML, Wright GL. Detection and characterization of the prostate specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer. 1995;62:552-8.
21. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81-5. (Pubitemid 27079448)
22. Mhawech-Fauceglia P, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using multiple tumour tissue microarray technique. Histopathology. 2007;50:472-83. (Pubitemid 46328190)
23. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109-22.
24. Bourke L, Kirkbride P, Hooper R, Rosario AJ, Chico TJ, Rosario DJ. Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness? Br J Cancer. 2013;108:9-13.
25. 11C]docetaxel and positron emission tomography. Clin Cancer Res. 2013;19:4163-73.